AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|
27.5 C
New York
Thursday, September 10, 2026

Tag: body

newssourceFORcompanyinformationcontent1releasesmarket

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Sleep Connection Pillowcase Shares Website Update Featuring Grounding Pillowcase With Reusable, Breathable Fabric and 5% Silver for Natural Sleep Support

The Sleep Connection Grounding Pillowcase now features enhanced product details highlighting silver-thread grounding technology, natural materials, and ease of use for wellness-focused routines 
The Sleep Connection Grounding Pillowcase now features enhanced product details highlighting silver-thread grounding technology, natural materials, and ease of use for wellness-focused routines

Jushi and Real Housewives Star Stacey Rusch Celebrate Successful Launch of Lifestyle Cannabis Brand ‘Shayo’

(Photo credit: Andreas Neumann)

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Cerapedics Announces FDA Approval of PearlMatrix™ P-15 Peptide Enhanced Bone Graft, The First and Only Proven Bone Growth Accelerator for Lumbar Fusion

ASPIRE pivotal Level-1 PMA IDE study evaluated PearlMatrix vs. local autograft in single-level TLIF procedures:- Demonstrated statistically superior fusion speed;- Achieved over twice as...

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Sakara Enters Clean Beauty Retailer Credo Beauty with New Beauty Biome Supplement

The holistic wellness leader expands its supplement category with new supplement Beauty Biome, now available alongside four other Sakara supplements at all Credo Beauty...

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBody

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers